Citigroup Issues Positive Forecast for Krystal Biotech (NASDAQ:KRYS) Stock Price

Krystal Biotech (NASDAQ:KRYS) had its price target lifted by Citigroup from $320.00 to $336.00 in a research note published on Monday morning,Benzinga reports. The firm currently has a buy rating on the stock.

Several other brokerages have also recently commented on KRYS. Zacks Research upgraded shares of Krystal Biotech from a “hold” rating to a “strong-buy” rating in a report on Wednesday, January 7th. Weiss Ratings restated a “hold (c+)” rating on shares of Krystal Biotech in a research report on Monday, December 29th. HC Wainwright reiterated a “buy” rating and set a $310.00 price objective (up from $240.00) on shares of Krystal Biotech in a research report on Friday. Chardan Capital boosted their target price on shares of Krystal Biotech from $216.00 to $220.00 and gave the company a “buy” rating in a research note on Tuesday, November 4th. Finally, Bank of America raised their target price on Krystal Biotech from $182.00 to $255.00 and gave the stock a “buy” rating in a research report on Friday, October 17th. One analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and one has assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average price target of $263.88.

Krystal Biotech Stock Up 4.1%

Shares of NASDAQ KRYS opened at $272.13 on Monday. The stock’s fifty day simple moving average is $229.04 and its 200 day simple moving average is $183.83. The stock has a market capitalization of $7.89 billion, a price-to-earnings ratio of 40.80 and a beta of 0.46. Krystal Biotech has a 52-week low of $122.80 and a 52-week high of $274.40.

Krystal Biotech (NASDAQ:KRYS) last released its quarterly earnings results on Monday, November 3rd. The company reported $2.66 earnings per share for the quarter, beating analysts’ consensus estimates of $1.12 by $1.54. The business had revenue of $97.80 million during the quarter, compared to analyst estimates of $93.72 million. Krystal Biotech had a return on equity of 19.36% and a net margin of 53.30%. As a group, analysts anticipate that Krystal Biotech will post 6.14 earnings per share for the current year.

Insider Transactions at Krystal Biotech

In other Krystal Biotech news, insider Suma Krishnan sold 25,000 shares of Krystal Biotech stock in a transaction on Thursday, December 4th. The shares were sold at an average price of $220.16, for a total transaction of $5,504,000.00. Following the completion of the sale, the insider owned 1,413,711 shares of the company’s stock, valued at $311,242,613.76. This trade represents a 1.74% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. 13.70% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Krystal Biotech

A number of hedge funds have recently modified their holdings of KRYS. SG Americas Securities LLC boosted its position in Krystal Biotech by 469.9% during the fourth quarter. SG Americas Securities LLC now owns 18,909 shares of the company’s stock valued at $4,662,000 after purchasing an additional 15,591 shares during the last quarter. GAMMA Investing LLC raised its stake in shares of Krystal Biotech by 58.8% during the 4th quarter. GAMMA Investing LLC now owns 789 shares of the company’s stock worth $195,000 after purchasing an additional 292 shares in the last quarter. CIBC Bancorp USA Inc. acquired a new stake in shares of Krystal Biotech during the 3rd quarter valued at about $467,000. Wilmington Savings Fund Society FSB grew its stake in shares of Krystal Biotech by 78.6% in the 3rd quarter. Wilmington Savings Fund Society FSB now owns 393 shares of the company’s stock valued at $69,000 after buying an additional 173 shares in the last quarter. Finally, Danske Bank A S bought a new stake in shares of Krystal Biotech in the 3rd quarter valued at approximately $35,000. 86.29% of the stock is owned by institutional investors and hedge funds.

More Krystal Biotech News

Here are the key news stories impacting Krystal Biotech this week:

• Positive Sentiment: Citigroup raised its price target to $336 and kept a Buy rating, implying sizable upside from the current price — a clear bullish signal from a major bank. Citigroup Price Target Raise
• Positive Sentiment: Company-reported preliminary results show strong commercial performance and balance sheet strength: Q4 VYJUVEK net revenue of $106–107M, full-year 2025 revenue guidance roughly $388–389M, and ~$955M cash on hand — supporting continued commercialization investment and pipeline funding. Business Update (GlobeNewswire)
• Positive Sentiment: Krystal highlighted positive interim results and next steps for its cystic fibrosis program KB407, suggesting meaningful clinical progress that could add long‑term value beyond VYJUVEK. KB407 Interim Results (Slideshow)
• Positive Sentiment: Analyst sentiment is broadly favorable — consensus is a “Buy” from the analyst community, and TD Cowen recently increased its price target to $306 — reinforcing buy-side confidence. Analyst Consensus TD Cowen PT Increase
• Neutral Sentiment: Short interest data published for January appears inconsistent (shows 0 shares and NaN change), so short-reporting does not provide a reliable explanation for today’s move. (Data likely noise/error.)
• Neutral Sentiment: The company presentation and transcript from the 44th Annual J.P. Morgan Healthcare Conference provide additional color on strategy and pipeline but largely reiterate the business update. J.P. Morgan Presentation Transcript

Krystal Biotech Company Profile

Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.

The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.